NCT02404480View on ClinicalTrials.gov

PTC596 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 6, 2017

Study Completion Date

February 6, 2017

Conditions
Cancer
Interventions
DRUG

PTC596

PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted

Trial Locations (4)

27708

Duke University, Durham

37203

Sarah Cannon Research Institute, Nashville

02215

Dana Farber Cancer Institute, Boston

M4Y2H8

Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY

NCT02404480 - PTC596 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter